In this editorial,the roles of orosomucoid(ORM)in the diagnoses and follow-up assessments of both nonneoplastic diseases and liver tumors are discussed with respect to the publication by Zhu et al presented in the pre...In this editorial,the roles of orosomucoid(ORM)in the diagnoses and follow-up assessments of both nonneoplastic diseases and liver tumors are discussed with respect to the publication by Zhu et al presented in the previous issue of World Journal of Gastroenterology(2020;26(8):840-817).ORM,or alpha-1 acid glycoprotein(AGP),is an acute-phase protein that constitutes 1%to 3%of plasma proteins in humans and is mainly synthesized in the liver.ORM exists in serum as two variants:ORM1 and ORM2.Although the variants share 89.6%sequence identity and have similar biological properties,ORM1 constitutes the main component of serum ORM.An interesting feature of ORM is that its biological effects differ according to variations in glycosylation patterns.This variable feature makes ORM an attractive target for diagnosing and monitoring many diseases,including those of the liver.Recent findings suggest that a sharp decrease in ORM level is an important marker for HBV-associated acute liver failure(ALF),and ORM1 plays an important role in liver regeneration.In viral hepatitis,increases in both ORM and its fucosylated forms and the correlation of these increases with fibrosis progression suggest that this glycoprotein can be used with other markers as a noninvasive method in the follow-up assessment of diseases.In addition,similar findings regarding the level of the asialylated form of ORM,called asialo-AGP(AsAGP),have been reported in a follow-up assessment of fibrosis in chronic liver disease.An increase in ORM in serum has also been shown to improve hepatocellular carcinoma(HCC)diagnosis performance when combined with other markers.In addition,determination of the ORM level has been useful in the diagnosis of HCC with AFP concentrations less than 500 ng/mL.For monitoring patients with AFP-negative HCC,a unique trifucosylated tetra-antennary glycan of ORM may also be used as a new potential marker.The fact that there are very few studies investigating the expression of this glycoprotein and its variants in liver tissues constitut展开更多
Porcine α-1 acid glycoprotein (AGP) in newborn pigs can be used to predict growth rate through weaning and is a marker for growth impairment. This study examined whether nutritional support can improve the growth rat...Porcine α-1 acid glycoprotein (AGP) in newborn pigs can be used to predict growth rate through weaning and is a marker for growth impairment. This study examined whether nutritional support can improve the growth rate of piglets identified as having poor growth potential. Cross-fostering (CF) and CF plus a milk supplement (CF + MS) were used to attempt to improve the growth performance of pigs. Blood was collected at d1 post-parturition for measurement of plasma AGP for all pigs in 28 litters contributing to the experiment. Piglets with the highest plasma AGP level were weight and sex matched to a littermate with a low plasma AGP concentration and four pairs of these weight and sex matched pigs were grouped into four foster litters per treatment (control, CF, CF + MS). The control group was assembled by pairing littermates remaining in donor litters. Pigs stayed on treatment until weaning at 21 days of age. At 35 days of age, dual energy X-ray absorptiometry (DXA) was performed on CF and CF + MS pigs to evaluate carcass composition. Control pairs differed in weaning weight, with pigs with higher plasma AGP at 1 day of age having smaller weaning weights than their littermates of similar birth weight (P < 0.05). However, CF eliminated the difference in weaning weight between the slow growing pigs and their birth weight matched littermates. CF + MS produced a similar effect as CF (P > 0.05). At 35 days of age, body weights were still similar between CF littermates and between CF + MS littermates (P > 0.05). DXA analysis demonstrated that body composition was similar between CF or CF + MS treated pigs and their littermates. These data demonstrate that CF can be used to correct the growth impairment in pigs predicted using plasma AGP as the marker. CF + MS can do the same, but at greater expense.展开更多
文摘In this editorial,the roles of orosomucoid(ORM)in the diagnoses and follow-up assessments of both nonneoplastic diseases and liver tumors are discussed with respect to the publication by Zhu et al presented in the previous issue of World Journal of Gastroenterology(2020;26(8):840-817).ORM,or alpha-1 acid glycoprotein(AGP),is an acute-phase protein that constitutes 1%to 3%of plasma proteins in humans and is mainly synthesized in the liver.ORM exists in serum as two variants:ORM1 and ORM2.Although the variants share 89.6%sequence identity and have similar biological properties,ORM1 constitutes the main component of serum ORM.An interesting feature of ORM is that its biological effects differ according to variations in glycosylation patterns.This variable feature makes ORM an attractive target for diagnosing and monitoring many diseases,including those of the liver.Recent findings suggest that a sharp decrease in ORM level is an important marker for HBV-associated acute liver failure(ALF),and ORM1 plays an important role in liver regeneration.In viral hepatitis,increases in both ORM and its fucosylated forms and the correlation of these increases with fibrosis progression suggest that this glycoprotein can be used with other markers as a noninvasive method in the follow-up assessment of diseases.In addition,similar findings regarding the level of the asialylated form of ORM,called asialo-AGP(AsAGP),have been reported in a follow-up assessment of fibrosis in chronic liver disease.An increase in ORM in serum has also been shown to improve hepatocellular carcinoma(HCC)diagnosis performance when combined with other markers.In addition,determination of the ORM level has been useful in the diagnosis of HCC with AFP concentrations less than 500 ng/mL.For monitoring patients with AFP-negative HCC,a unique trifucosylated tetra-antennary glycan of ORM may also be used as a new potential marker.The fact that there are very few studies investigating the expression of this glycoprotein and its variants in liver tissues constitut
文摘Porcine α-1 acid glycoprotein (AGP) in newborn pigs can be used to predict growth rate through weaning and is a marker for growth impairment. This study examined whether nutritional support can improve the growth rate of piglets identified as having poor growth potential. Cross-fostering (CF) and CF plus a milk supplement (CF + MS) were used to attempt to improve the growth performance of pigs. Blood was collected at d1 post-parturition for measurement of plasma AGP for all pigs in 28 litters contributing to the experiment. Piglets with the highest plasma AGP level were weight and sex matched to a littermate with a low plasma AGP concentration and four pairs of these weight and sex matched pigs were grouped into four foster litters per treatment (control, CF, CF + MS). The control group was assembled by pairing littermates remaining in donor litters. Pigs stayed on treatment until weaning at 21 days of age. At 35 days of age, dual energy X-ray absorptiometry (DXA) was performed on CF and CF + MS pigs to evaluate carcass composition. Control pairs differed in weaning weight, with pigs with higher plasma AGP at 1 day of age having smaller weaning weights than their littermates of similar birth weight (P < 0.05). However, CF eliminated the difference in weaning weight between the slow growing pigs and their birth weight matched littermates. CF + MS produced a similar effect as CF (P > 0.05). At 35 days of age, body weights were still similar between CF littermates and between CF + MS littermates (P > 0.05). DXA analysis demonstrated that body composition was similar between CF or CF + MS treated pigs and their littermates. These data demonstrate that CF can be used to correct the growth impairment in pigs predicted using plasma AGP as the marker. CF + MS can do the same, but at greater expense.
